Literature DB >> 28769200

RENAL TRANSPLANTATION - AN EARLY EXPERIENCE.

R K Malik1, V K Saxena2, T K Sahni3, K R Nair2, V S Kolhe4.   

Abstract

Renal transplant (RT) is now a therapy of choice for end stage renal disease (ESRD). The Nephrology Unit, Asvini started functioning in Dec 90 and to date 1298 sittings of hemodialysis have been given to 45 patients. Of these, 35 were in ESRD and 11 patients underwent renal transplantation at this hospital during the period Jan 91 - Dec 93. One patient expired after 18 months of transplantation due to infection. Early experience in screening patients for RT, use of immunosuppression, management of rejection episodes and protocol are presented with special emphasis on its relevance to the Armed Forces.

Entities:  

Keywords:  Immunosuppression; Rejection; Renal Failure; Transplantation

Year:  2017        PMID: 28769200      PMCID: PMC5529722          DOI: 10.1016/S0377-1237(17)31059-6

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  5 in total

1.  Does cyclosporine improve the results of HLA-identical renal transplantation?

Authors:  S M Flechner; R H Kerman; C T Van Buren; M I Lorber; C J Barker; B D Kahan
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

2.  Renal transplantation in India-problems and prospects.

Authors:  M A Muthusethupathi; S Shivakumar
Journal:  J Assoc Physicians India       Date:  1993-03

3.  Influence of sex on histocompatibility matching in renal transplantation.

Authors:  G Opelz; P I Terasaki
Journal:  Lancet       Date:  1977-08-27       Impact factor: 79.321

4.  Experience with renal transplantation in Rajasthan.

Authors:  A K Sharma; S L Tolani; G L Rathi; R Gupta; P Chhablani
Journal:  J Assoc Physicians India       Date:  1993-01

5.  Cyclosporin A in patients receiving renal allografts from cadaver donors.

Authors:  R Y Calne; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; B D Pentlow; K Rolles
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.